JP2023522730A5 - - Google Patents

Info

Publication number
JP2023522730A5
JP2023522730A5 JP2022564073A JP2022564073A JP2023522730A5 JP 2023522730 A5 JP2023522730 A5 JP 2023522730A5 JP 2022564073 A JP2022564073 A JP 2022564073A JP 2022564073 A JP2022564073 A JP 2022564073A JP 2023522730 A5 JP2023522730 A5 JP 2023522730A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
variable region
chain variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522730A (ja
JP7763780B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/089059 external-priority patent/WO2021213475A1/zh
Publication of JP2023522730A publication Critical patent/JP2023522730A/ja
Publication of JP2023522730A5 publication Critical patent/JP2023522730A5/ja
Priority to JP2024218813A priority Critical patent/JP2025038088A/ja
Application granted granted Critical
Publication of JP7763780B2 publication Critical patent/JP7763780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564073A 2020-04-22 2021-04-22 抗cd73/抗pd-1二重特異性抗体及びその使用 Active JP7763780B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218813A JP2025038088A (ja) 2020-04-22 2024-12-13 抗cd73/抗pd-1二重特異性抗体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010324783 2020-04-22
CN202010324783.4 2020-04-22
CN202110270671.X 2021-03-12
CN202110270671 2021-03-12
PCT/CN2021/089059 WO2021213475A1 (zh) 2020-04-22 2021-04-22 抗cd73-抗pd-1双特异性抗体及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218813A Division JP2025038088A (ja) 2020-04-22 2024-12-13 抗cd73/抗pd-1二重特異性抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2023522730A JP2023522730A (ja) 2023-05-31
JP2023522730A5 true JP2023522730A5 (cg-RX-API-DMAC7.html) 2023-07-10
JP7763780B2 JP7763780B2 (ja) 2025-11-04

Family

ID=78094648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022564073A Active JP7763780B2 (ja) 2020-04-22 2021-04-22 抗cd73/抗pd-1二重特異性抗体及びその使用
JP2024218813A Pending JP2025038088A (ja) 2020-04-22 2024-12-13 抗cd73/抗pd-1二重特異性抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218813A Pending JP2025038088A (ja) 2020-04-22 2024-12-13 抗cd73/抗pd-1二重特異性抗体及びその使用

Country Status (13)

Country Link
US (1) US20230151111A1 (cg-RX-API-DMAC7.html)
EP (1) EP4141033A4 (cg-RX-API-DMAC7.html)
JP (2) JP7763780B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004726A (cg-RX-API-DMAC7.html)
CN (1) CN113527501B (cg-RX-API-DMAC7.html)
AU (2) AU2021261803B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021426A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176321A1 (cg-RX-API-DMAC7.html)
IL (1) IL297432A (cg-RX-API-DMAC7.html)
MX (1) MX2022013311A (cg-RX-API-DMAC7.html)
PH (1) PH12022552785A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021213475A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211405B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗cd73抗体及びその使用
CN118530342A (zh) * 2021-03-12 2024-08-23 中山康方生物医药有限公司 降低免疫细胞分泌il-8和/或il-6的水平的方法
IL286430A (en) * 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4321537A4 (en) * 2022-06-22 2025-04-23 Akeso Biopharma, Inc. Pharmaceutical composition and use thereof
CN116813786B (zh) * 2023-08-03 2024-11-26 贝达药业股份有限公司 抗cd73抗体及其应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
RS62003B2 (sr) * 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
JP6805142B2 (ja) * 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法
IL290457B2 (en) * 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
AU2017228470A1 (en) * 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN116271014A (zh) * 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CA3080976A1 (en) * 2017-11-06 2019-05-09 Corvus Pharmaceuticals, Inc. Adenosine pathway inhibitors for cancer treatment
AU2019231172B2 (en) * 2018-03-09 2023-08-24 Phanes Therapeutics, Inc. Anti-CD73 antibodies and uses thereof
CA3096674A1 (en) * 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
CN112041348B (zh) 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2021213466A1 (zh) 2020-04-22 2021-10-28 中山康方生物医药有限公司 抗cd73的抗体及其用途

Similar Documents

Publication Publication Date Title
US11845795B2 (en) NKp46 binding proteins
US11202828B2 (en) Therapeutic SIRP-α antibodies
RU2767357C2 (ru) Биспецифические антитела-ингибиторы контрольных точек
EP3405492B1 (en) Multispecific molecules targeting cll-1
JP2022542450A5 (cg-RX-API-DMAC7.html)
CN115175702A (zh) 用于体内生物靶向的材料和方法
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
CA2936785A1 (en) Bi-specific cd3 and cd19 antigen-binding constructs
CA2903056A1 (en) Tetravalent bispecific antibodies
US20230279108A1 (en) Therapeutic sirp-alpha antibodies
CN115175938A (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
JP2025038088A (ja) 抗cd73/抗pd-1二重特異性抗体及びその使用
JP2024515396A5 (cg-RX-API-DMAC7.html)
US20250270315A1 (en) Novel anti-sirpa antibodies
JP2024540148A5 (cg-RX-API-DMAC7.html)
AU2022332499A1 (en) Fap/cd40 binding molecule and medicinal use thereof
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
CA3255392A1 (en) Anti-Dectin-1 Antibodies and Their Methods of Use
AU2021224787A1 (en) CD137 binding molecules and uses thereof
WO2018237364A1 (en) Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in caner therapy
RU2024107310A (ru) Радиоконъюгаты к psma и способы их применения
HK40073540A (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法